July 2009
Takeda v. Mylan: High-Cost Generic Drugs from Baseless Paragraph IV CertificationsBy Gregory M. York
In Takeda v. Mylan, the Federal Circuit revisited attorney fees in the context of an ANDA application. In doing so, the court provided additional guidance regarding factual circumstances that may support such awards and addressed several of the unanswered questions from the Yamanouchi v. Danbury opinion.
Subscribers: click here for the full story
Non-Subscribers: click here to subscribe
Pay per view ($20.00)
